Artivion stock
AORTNYSEArtivion, Inc., HealthcareISIN US2289031005
32Score 32 out of 100, Weak
Price and trend
30 / 100
Price history
−59% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 32% below it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 36).
The price is 59% below its 52-week high. Largest decline in 20 years: 76% (September 2008 to March 2009).
Chart figures for advanced users
- SMA 50$23.02
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$28.45
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)36
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.40
- The lowest closing price of the last twelve months.
- Resistance$47.63
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Artivion, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $945.87M, is number 60 of 90 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $488.89M (up 10.8%) and adjusted earnings per share of −$0.32.
- MEQIRI Score 32 out of 100 (Weak): rank 667 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $6.36, with the price 216% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Above fair valuePrice 216% above the fair value of $6.36.Valuation 14
- Loss-makingLoss of $17.59M over the last 12 months.Fundamentals 31
- DilutionShare count up 20% since 2020.Capital allocation 20
The score is held back by capital allocation and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 33 to 32.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak fundamentals
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $4.54 and expensive above $10.59 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $5.47, at 8.7% it would be $7.61.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14% on the twelve months before. Revenue has grown solidly since 2006, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 61%, operating 6%, net 2%. Last 12 months: net −4%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 5 Nov 2026EPS reported $0.08 (expected −$0.06)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 17.5% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.32−17.5%
- Revenue
- $488.89M−0.3%
- Earnings per share
- $0.24−16.2%
- Revenue
- $534.52M−1.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +3.6%2026 guidance reiterated: growth of 7% to 11%, revenue of $480 to $496 million and adjusted EBITDA of $92 to $99 million, with more confidence after the approval.
“We continue to expect adjusted constant currency growth between 7% to 11% for the full year, representing a reported revenue range of $480 million to $496 million. This guidance contemplates FX to have an approximate 1 percentage point tailwind on as reported revenue for the full year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $3.51M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Green Andrew MSale
10 Sept 2026, SVP, Regulatory and Quality
- Shares
- 11,480
- Price
- $24.97
- Value
- $286,656
- Green Andrew MSale
3 Sept 2026, SVP, Regulatory and Quality
- Shares
- 1,493
- Price
- $26.02
- Value
- $38,842
- Green Andrew MSale
2 Sept 2026, SVP, Regulatory and Quality
- Shares
- 6,510
- Price
- $27.27
- Value
- $177,495
Show 5 more
- Mackin James PSale
19 Aug 2026, President & CEO
- Shares
- 70,000
- Price
- $28.96
- Value
- $2.03M
- Green Andrew MSale
14 Aug 2026, SVP, Regulatory and Quality
- Shares
- 616
- Price
- $28.55
- Value
- $17,586
- Berry Lance ASale
14 Aug 2026, EVP, COO, CFO & Treasurer
- Shares
- 715
- Price
- $28.55
- Value
- $20,413
- Holloway Jean FSale
12 Aug 2026, SVP, General Counsel
- Shares
- 977
- Price
- $28.49
- Value
- $27,835
- Green Andrew MSale
11 Jun 2026, SVP, Regulatory and Quality
- Shares
- 44,001
- Price
- $20.70
- Value
- $910,739
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Artivion
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- SI-BONESIBN $1.13B47
- IRadimedIRMD $1.11B77
- CeriBellCBLL $1.08B49
- AdaptHealthAHCO $1.06B33
- Kuros BiosciencesKURN.SW $962.93M47
- OrthoPediatricsKIDS $879.14M47
- MedCapMCAP.ST $828.57M76
- Beta BionicsBBNX $801.27M47
ETFs that hold Artivion
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.03% | 0.49% | €318.39M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.08% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.03% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 21 Feb 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.